These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 23229562)

  • 21. Cardiotoxicity evaluation using human embryonic stem cells and induced pluripotent stem cell-derived cardiomyocytes.
    Zhao Q; Wang X; Wang S; Song Z; Wang J; Ma J
    Stem Cell Res Ther; 2017 Mar; 8(1):54. PubMed ID: 28279214
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cell-based two-dimensional morphological assessment system to predict cancer drug-induced cardiotoxicity using human induced pluripotent stem cell-derived cardiomyocytes.
    Matsui T; Miyamoto K; Yamanaka K; Okai Y; Kaushik EP; Harada K; Wagoner M; Shinozawa T
    Toxicol Appl Pharmacol; 2019 Nov; 383():114761. PubMed ID: 31533062
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improving reliability and reducing costs of cardiotoxicity assessments using laser-induced cell poration on microelectrode arrays.
    Iachetta G; Colistra N; Melle G; Deleye L; Tantussi F; De Angelis F; Dipalo M
    Toxicol Appl Pharmacol; 2021 May; 418():115480. PubMed ID: 33689843
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High-Content Assay Multiplexing for Toxicity Screening in Induced Pluripotent Stem Cell-Derived Cardiomyocytes and Hepatocytes.
    Grimm FA; Iwata Y; Sirenko O; Bittner M; Rusyn I
    Assay Drug Dev Technol; 2015 Nov; 13(9):529-46. PubMed ID: 26539751
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells.
    Sharma A; Burridge PW; McKeithan WL; Serrano R; Shukla P; Sayed N; Churko JM; Kitani T; Wu H; Holmström A; Matsa E; Zhang Y; Kumar A; Fan AC; Del Álamo JC; Wu SM; Moslehi JJ; Mercola M; Wu JC
    Sci Transl Med; 2017 Feb; 9(377):. PubMed ID: 28202772
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An impedance-based cellular assay using human iPSC-derived cardiomyocytes to quantify modulators of cardiac contractility.
    Scott CW; Zhang X; Abi-Gerges N; Lamore SD; Abassi YA; Peters MF
    Toxicol Sci; 2014 Dec; 142(2):331-8. PubMed ID: 25237062
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Human hepatocytes derived from pluripotent stem cells: a promising cell model for drug hepatotoxicity screening.
    Gómez-Lechón MJ; Tolosa L
    Arch Toxicol; 2016 Sep; 90(9):2049-2061. PubMed ID: 27325232
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The case for induced pluripotent stem cell-derived cardiomyocytes in pharmacological screening.
    Khan JM; Lyon AR; Harding SE
    Br J Pharmacol; 2013 May; 169(2):304-17. PubMed ID: 22845396
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A multi-parameter in vitro screen in human stem cell-derived cardiomyocytes identifies ponatinib-induced structural and functional cardiac toxicity.
    Talbert DR; Doherty KR; Trusk PB; Moran DM; Shell SA; Bacus S
    Toxicol Sci; 2015 Jan; 143(1):147-55. PubMed ID: 25304212
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cardiotoxicity screening: a review of rapid-throughput in vitro approaches.
    Li X; Zhang R; Zhao B; Lossin C; Cao Z
    Arch Toxicol; 2016 Aug; 90(8):1803-16. PubMed ID: 26676948
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessment of Cardiotoxicity With Stem Cell-based Strategies.
    Stella Stoter AM; Hirt MN; Stenzig J; Weinberger F
    Clin Ther; 2020 Oct; 42(10):1892-1910. PubMed ID: 32938533
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CSAHi study: Validation of multi-electrode array systems (MEA60/2100) for prediction of drug-induced proarrhythmia using human iPS cell-derived cardiomyocytes -assessment of inter-facility and cells lot-to-lot-variability.
    Nozaki Y; Honda Y; Watanabe H; Saiki S; Koyabu K; Itoh T; Nagasawa C; Nakamori C; Nakayama C; Iwasaki H; Suzuki S; Washio I; Takahashi E; Miyamoto K; Yamanishi A; Endo H; Shinozaki J; Nogawa H; Kunimatsu T
    Regul Toxicol Pharmacol; 2016 Jun; 77():75-86. PubMed ID: 26884090
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical and Research Tools for the Study of Cardiovascular Effects of Cancer Therapy.
    Feroze RA; Leya J; Herron T; Hayek SS
    J Cardiovasc Transl Res; 2020 Jun; 13(3):417-430. PubMed ID: 32472498
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Population-based toxicity screening in human induced pluripotent stem cell-derived cardiomyocytes.
    Burnett SD; Blanchette AD; Grimm FA; House JS; Reif DM; Wright FA; Chiu WA; Rusyn I
    Toxicol Appl Pharmacol; 2019 Oct; 381():114711. PubMed ID: 31425687
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cardiotoxicity Hazard and Risk Characterization of ToxCast Chemicals Using Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes from Multiple Donors.
    Burnett SD; Blanchette AD; Chiu WA; Rusyn I
    Chem Res Toxicol; 2021 Sep; 34(9):2110-2124. PubMed ID: 34448577
    [TBL] [Abstract][Full Text] [Related]  

  • 36. hiPSC-CM Monolayer Maturation State Determines Drug Responsiveness in High Throughput Pro-Arrhythmia Screen.
    da Rocha AM; Campbell K; Mironov S; Jiang J; Mundada L; Guerrero-Serna G; Jalife J; Herron TJ
    Sci Rep; 2017 Oct; 7(1):13834. PubMed ID: 29061979
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiac safety pharmacology: from human ether-a-gogo related gene channel block towards induced pluripotent stem cell based disease models.
    Kraushaar U; Meyer T; Hess D; Gepstein L; Mummery CL; Braam SR; Guenther E
    Expert Opin Drug Saf; 2012 Mar; 11(2):285-98. PubMed ID: 22103746
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High-throughput cardiac safety evaluation and multi-parameter arrhythmia profiling of cardiomyocytes using microelectrode arrays.
    Gilchrist KH; Lewis GF; Gay EA; Sellgren KL; Grego S
    Toxicol Appl Pharmacol; 2015 Oct; 288(2):249-57. PubMed ID: 26232523
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical Trial in a Dish: Using Patient-Derived Induced Pluripotent Stem Cells to Identify Risks of Drug-Induced Cardiotoxicity.
    Lam CK; Wu JC
    Arterioscler Thromb Vasc Biol; 2021 Mar; 41(3):1019-1031. PubMed ID: 33472401
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Human Induced Pluripotent Stem Cell (hiPSC)-Derived Cells to Assess Drug Cardiotoxicity: Opportunities and Problems.
    Magdy T; Schuldt AJT; Wu JC; Bernstein D; Burridge PW
    Annu Rev Pharmacol Toxicol; 2018 Jan; 58():83-103. PubMed ID: 28992430
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.